NORML

JANUARY 4, 2019

Happy New Year and welcome to the first Weekly Legislative Roundup of 2019! The new Congress was just sworn in yesterday, and they are not wasting any time. At the state level, Alaska regulators have voted in favor of plans to permit on-site marijuana consumption at designated retailers.

Legislation 122

Legislation Clinical Trials Research and Development Access 122

The Cannigma

FEBRUARY 2, 2021

In 2019, Parkinson’s UK announced the launch of a major £1.2 million clinical trial investigating the effects of CBD on hallucinations and delusions related to the disease. Still, research is ongoing. The post Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It appeared first on The Cannigma.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

The Blunt Truth

AUGUST 13, 2019

In March of 2019, the FDA established a Working Group to determine the possible legislative pathways to regulate CBD. On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Peninsula Alternative Health

MAY 15, 2019

The huge difference between medical cannabis and traditional pharmaceuticals is that cannabis is quickly becoming accessible to treat conditions before clinical trials and standard dosing protocols have been established. 2019) Cannabis may help relieve Autism symptoms, Israeli study shows. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MedicalJane

MAY 21, 2020

Researchers at The University of New Mexico (UNM) have conducted a series of recent studies testing the effectiveness and safety of consuming cannabis, but this is the first study they have conducted measuring the therapeutic potential of hemp oil with low THC levels. The Hemp Farming Act of 2018.

Oil 100

Oil Hemp Extraction Clinical Trials 100

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time. Ksana Health – www.ksanahealth.com.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

The Cannigma

AUGUST 31, 2021

The researchers stated that these knowledge gaps must be addressed and that “clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”. People want to trust their doctors, but doctors need knowledge” (Shutterstock).

Education 101

Education Clinical Trials Medicine Policy 101

LifeCannMD

AUGUST 2, 2024

More clinical trials are needed to establish definitive efficacy and safety profiles. – Details: The research emphasized the need for controlled clinical trials to better understand the optimal dosages and strains. The study also noted that patients using medical cannabis had improved quality of life.

Clinical Trials 52

Clinical Trials Marijuana Research and Development Cannabinoids 52

Cannabis Law Report

JUNE 25, 2021

In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Examples of skin cancer drug include 5-FU, Aldara and Efudex.

Research and Development 65

Research and Development Therapy Pharmaceutical Clinical Trials 65

Project CBD

FEBRUARY 28, 2023

Sales appear to have peaked in 2019, when natural channel consumers spent more than $90.7 Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. million on these products.

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

JANUARY 23, 2020

” The systematic review of the literature “was conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted).”

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

The Cannigma

JULY 1, 2022

The highest quality form of scientific research, in terms of whether the results provide predictive power (which is what science is all about), is the placebo controlled, double blind, randomized clinical trial. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.

Research and Development 108

Research and Development Data THC Clinical Trials 108

SpeedWeed

JULY 6, 2021

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. Several prestigious American universities have launched their own psychedelics centers in the past decade.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 45

Policy Safety Marijuana Data 45

Cannabis Law Report

OCTOBER 9, 2021

Indeed, studies conducted by world renowned medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of conditions including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress. Please join us in cosponsoring this legislation, thank you.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

JUNE 4, 2021

It seems completely backwards that an unregulated product that gets people “high” and is synthesized in a lab can be sold at gas stations and smoke shops but naturally derived Delta 9-THC must go through rigorous safety testing and can only be sold and handled by licensed companies.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance. 2014): 86-95. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

AUGUST 19, 2019

To obtain registration, a drug sponsor is generally required to run large-scale clinical trials proving safety and efficacy and provide the resulting evidence to the TGA. In Australia, drugs that doctors prescribe conventionally have obtained ‘registration’ with the TGA.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 24, 2019

NICE guideline [NG144] Published date: November 2019. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. the person’s clinical condition is stable. 1 ] November 2019. [ Cannabis-based medicinal products. Tools and resources. Recommendations. Recommendations for research.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Peninsula Alternative Health

MAY 15, 2019

The huge difference between medical cannabis and traditional pharmaceuticals is that cannabis is quickly becoming accessible to treat conditions before clinical trials and standard dosing protocols have been established. 2019) Cannabis may help relieve Autism symptoms, Israeli study shows. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

SEPTEMBER 24, 2019

September 23, 2019. We are very happy that patients will now have access to a much-needed, new treatment option, and one routed through a rigorous clinical trials programme and licensed by the EMA.”. PDF Version. LONDON and CARLSBAD, Calif.,

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. The study also concludes that more clinical trials are required to take place before an accurate assessment on the use of cbd oil for autism can be made. As far-fetched as it sounds, the negative side of CBD is pretty blank.

Treatment 76

Treatment Oil CBD Therapy 76

The Cannigma

JUNE 15, 2021

In testimony before the Senate in 2019, then-FDA Deputy Commissioner Dr. Amy Abernethy clarified that CBD products may not be marketed as food or food supplements. But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them. Shutterstock). Kevin McGovern/Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JANUARY 11, 2019

However, we firmly disagree that the referenced clinical trials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited. CBD has been found to be generally well tolerated with a good safety profile.”.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

JULY 23, 2019

In April 2019 Thurston filed a class action lawsuit in California against Koi CBD, suing it for violations of California State Unfair Competition and Consumer Legal Remedies Laws and the Pennsylvania Unfair Trade Practices and Consumer Protection Law. She lost her job as a result.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

JULY 24, 2019

July 22, 2019. Examples of claims observed on your website and social media accounts in April 2019 that establish the intended use of your products as drugs include, but may not be limited to, the following: On your product webpage for CBD Disposable Vape Pen (Relieve): • “[F]or chronic pain.”. RETURN RECEIPT REQUESTED. Curaleaf, Inc.

CBD 51

CBD Tincture Pets Chronic Pain 51

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. 2019): 3. [3] Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

AUGUST 21, 2019

However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinical trial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JULY 9, 2021

Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The latter remains a dangerous drug and is considered higher risk for treatment than CBD (TGA 2019 ).

Research and Development 52

Research and Development Medicine Access Media 52

TheAnswerPage

JANUARY 11, 2022

For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Published 2019 May 6. Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. 2019;14(5):e0216556. doi:10.1371/journal.pone.0216556.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

AUGUST 5, 2021

billion in 2019. Thanks to the license, Filament will look to create the first-ever natural pharmaceutical grade extracts and put them into clinical trials in order to demonstrate safety and efficacy. Over the next several years, the psychedelics industry is expected to grow at a compound annual growth rate of 16.3

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA 92

DEA Research and Development Cultivation Supply Chain 92